SeaStar Medical Holding Corp's stock increased by 5.10% as it crossed above the 5-day SMA. This rise follows the FDA's decision to reduce the mandatory enrollment size for the SAVE Surveillance Registry from 300 to 50 patients, indicating confidence in the safety of QUELIMMUNE therapy.
The reduction in patient enrollment is expected to accelerate the market adoption of QUELIMMUNE therapy, which has shown promising survival rates in preliminary results. Among the first 21 patients, the therapy reported zero device-related adverse events and a 70% survival rate at 90 days, providing hope for pediatric patients suffering from acute kidney injury.
This development not only enhances SeaStar Medical's revenue potential by facilitating smoother adoption of QUELIMMUNE therapy but also positions the company to capture a share of the estimated $100 million pediatric acute kidney injury market in the U.S.
Wall Street analysts forecast ICU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ICU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.335
Low
1.00
Averages
1.00
High
1.00
Current: 2.335
Low
1.00
Averages
1.00
High
1.00
No data
About ICU
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
